Bristol Myers Squibb

Q3 2026
Speakers

Oct 29, 2026 · 61 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Welcome to the Bristol Meyer Squib Third Quarter 2026 Earnings Conference Call. All participants will be in a listen only ?mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two.

Please note this event is being recorded.
?I would now like to turn the conference over to Chuck Triano, Senior Vice President and Head of Investor Relations. Please go ahead.

Passages & reports (6)
  • Welcome to the Bristol Meyer Squib Third Quarter 2026 Earnings Conference Call. All partic…
  • mode.
  • Should you need assistance, please signal a conference specialist by pressing the star key…
  • two. Please note this event is being recorded.
  • I
  • would now like to turn the conference over to Chuck Triano, Senior Vice President and Head…

Speaker 1

Unverified voice label

Thank you, and good morning, everyone. We appreciate you joining our third quarter 2026 earnings call. With me this morning with prepared remarks are Chris Berner, our board chair and chief executive officer, and David Elkins, our chief financial officer. Also participating in today's call is Adam Lenkowski, our Chief Commercialization Officer, and Christian Massachese, our Chief Medical Officer and Head of Global Drug Development.

Earlier this morning, we posted our quarterly slide presentation to BMS.com that you can use to follow along with Chris and David's remarks. Before we get started, I'll remind everybody that during this call, we will make statements about the company's future plans and prospects
that constitute forward looking statements. Actual results may differ materially from those indicated by those forward looking statements as a result of various important factors, including those discussed in the company's SEC filings.

These forward looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of
any future date. And we specifically disclaim any obligation to update forward looking statements, even if our estimates change. We'll also focus our comments on our non gap financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non gap financial measures to the most comparable gap measures are available at BMS.com.

Finally, unless otherwise stated, all comparisons are made from the same period in 2025, and sales growth rates will be discussed on an underlying basis, which excludes the impact of foreign exchange. All references to our PL are on a non-gap basis. And with that, I'll hand it over to Chris.

Passages & reports (5)
  • Thank you, and good morning, everyone. We appreciate you joining our third quarter 2026 ea…
  • our Chief Medical Officer and Head of Global Drug Development. Earlier this morning, we po…
  • that constitute forward looking statements. Actual results may differ materially from thos…
  • any future date. And we specifically disclaim any obligation to update forward looking sta…
  • BMS.com. Finally, unless otherwise stated, all comparisons are made from the same period i…

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 2

Unverified voice label

Chuck. Good morning, everyone, and thank you for joining our Q3 2026 earnings call. We reported another quarter of digit growth in our growth portfolio and progressed our plans to de-risk the pipeline to position the company for long-term success. We have seen several positive registrational readouts and regulatory approvals over the past few months, and we expect more to come, bringing the next wave of launches into sharper focus. ?

We
are executing well commercially, ?our differentiated pipeline is advancing nicely, and we continue to operate with discipline, which gives us strategic flexibility to invest for sustainable growth. Based on the strength of our results, we are raising our full year guidance. David will provide additional details on this shortly. Let me start with our Q3 performance on slide four. ?Our growth portfolio continues to deliver solid results with sales increasing 12%, driven by a broad set of differentiated products.

We generated strong performance in key brands including Reblazil, Brianzi, OptuLag, Cuvantic, and Camzios. We also continue to expand the reach of our medicines. In September, Camzios
received approval for an expanded indication and became the only FDA approved therapy for pediatric patients with obstructive HCM. We also achieved an important milestone in the quarter with the FDA's accelerated approval of Zimbexis, the first approved cell mod, and the newest addition to our portfolio.

Zimbexis is approved for the
treatment of multiple myeloma, where the combination of a highly efficacious and convenient oral option is an important treatment advancement for patients in both community and academic settings. We are encouraged by positive early launch feedback and by the compelling phase three data we announced earlier this month, where Zimbexis demonstrated a meaningful improvement in progression free survival. We will present these data at ASH in December.

These results further strengthen our conviction in cell mods
?and our broader targeted protein degradation platform, where BMS is a clear leader. Behind Zimbexis, our second cell mod, Mazigdomide, has a PADUFA date of May 13, 2027. Mazygdomide offers the potential to introduce another highly efficacious and convenient oral option for a different segment of multiple myeloma patients. We also continue to advance glaucotamide in lymphoma and will present the first phase two data in frontline follicular lymphoma at ASH.

The momentum in our late stage pipeline has accelerated. In the past two months alone, we announced positive data for four registrational studies. These include Zymbexis
PFS, as I mentioned earlier, admilparent in idiopathic pulmonary fibrosis, interim results for rays 101 in GEP nets, and R low cell in relapsed and refractory multiple myeloma. Let me comment on the last three. Admirant, met its primary endpoint at the 60 milligram dose with a favorable safety and tolerability profile that supports its potential as a first in class IPF treatment.

IPF is a progressive and often fatal disease where there remains a need for effective, well tolerated treatment options like admilparint. We will discuss the IPF results with regulators and expect phase three results in progressive pulmonary fibrosis in the first quarter of
next year. PPF is a larger opportunity in another area where admilparin has significant commercial potential. With respect to RAISE 101, our tinium-based radiopharmaceutical therapy, we're encouraged by the interim readouts in GEPNATs.

These results demonstrated a clinically meaningful improvement in PFS
in patients whose disease has progressed following existing lutetium-based therapy. These were the first phase three results for an alpha-emitting targeted RPT, representing an important milestone for RAIS 101 and further strengthening our conviction in radiopharmaceuticals as a platform. We are engaging with the FDA on next steps towards regulatory submission. Finally, RLOSAL, our GPRC 5D direct at CART, delivered positive results ?in the registrational phase two quintessential study this September, a milestone that underscores its potential to set a new standard of care in the post-BCMA multiple myeloma market.

This study represents the only prospective trial exclusively conducted in the post-BCMA quadruple class exposed setting, a growing patient population with
poor outcomes and no therapies approved specifically for this segment. As these programs advance, we are building the Manufacturing Foundation for the next generation of our medicines with two U.S. investments recently announced. In Houston, we shared plans for a new state of the art manufacturing campus at Generation Park, an approximately $2.3 billion investment that will create nearly 500 skilled jobs.

This facility
?will give us manufacturing flexibility across small molecules, biologics, and antibody drug conjugates. It is also designed to evolve and scale to meet patient needs for decades to ?come. In Indiana, RAISE Bio is investing more than $170 million to establish a new radio pharmaceutical manufacturing facility, complementing its existing footprint in the state and creating up to 100 new jobs by the end of 2029.

Together, these investments support the next wave of medicines coming through our
pipeline and advance our U.S. manufacturing commitments. Turning to slide five, as we look ahead, we have several meaningful readouts over the remainder of 2026 and into 2027. Before year end, we expect phase three data for MOLVEXIAN and secondary stroke prevention and SOTIC 2 and LUPIS. ?With COBINFI, we will share open label Alzheimer's disease psychosis data from the ADEP 1 and from the Long-Term Extension ADEP 3 studies at CTAD next month.

In 2027, we continue to expect results for MILVECIN and atrial fibrillation in the first quarter. We also anticipate additional data from the broader ADEP
program, bipolar one data from the COBINFI balsam studies, and the first registrational registrational data for golcotamide in high-risk first line LBCL. ?So while we have made good progress in our pipeline, there's more to ?come. As we close out the year and move into 2027, we are focused on a few key priorities as noted on slide six.

First, sustaining the momentum across our growth portfolio. We now have eight growth portfolio medicines, each annualizing over $1 billion based on Q3 sales, giving us a broad base of growth drivers.
Second, translating pipeline progress into filings, approvals, and successful launches. Zinbexis is an early example of that progression, and as additional studies read out, our focus will be on launch preparedness and moving with urgency to bring these medicines to patients.

Third, continuing to rewire how we operate. We're
focused on becoming faster and more efficient in RD, and over the past year, we have made changes across the organization to strengthen how we design and conduct clinical trials. At the same time, we continue to drive productivity and efficiency, including through our organizational structure, capital allocation decision making process, and the use of technology. That discipline gives us flexibility to invest behind the growth portfolio and pipeline, pursue business development where it makes sense, and return cash to shareholders.

Taken together, we are entering the final quarter of the year with real momentum. Our growth portfolio is performing well. We're advancing our pipeline with
meaningful wins, ?and remain highly disciplined in ensuring our cost structure is aligned with our revenue base. The team is energized and focused on delivering value for patients and our shareholders. With that, I'll turn it over to David.

Passages & reports (42)
  • Chuck. Good morning, everyone, and thank you for joining our Q3 2026 earnings call. We rep…
  • months, and we expect more to come, bringing the next wave of launches into sharper focus.
  • We
  • are executing well commercially,
  • our
  • differentiated pipeline is advancing nicely, and we continue to operate with discipline, w…
  • four.
  • Our
  • growth portfolio continues to deliver solid results with sales increasing 12%, driven by a…
  • received approval for an expanded indication and became the only FDA approved therapy for …
  • treatment of multiple myeloma, where the combination of a highly efficacious and convenien…
  • progression free survival. We will present these data at ASH in December. These results fu…
  • and
  • our broader targeted protein degradation platform, where BMS is a clear leader. Behind Zim…
  • myeloma patients. We also continue to advance glaucotamide in lymphoma and will present th…
  • PFS, as I mentioned earlier, admilparent in idiopathic pulmonary fibrosis, interim results…
  • profile that supports its potential as a first in class IPF treatment. IPF is a progressiv…
  • next year. PPF is a larger opportunity in another area where admilparin has significant co…
  • in patients whose disease has progressed following existing lutetium-based therapy. These …
  • steps towards regulatory submission. Finally, RLOSAL, our GPRC 5D direct at CART, delivere…
  • in
  • the registrational phase two quintessential study this September, a milestone that undersc…
  • poor outcomes and no therapies approved specifically for this segment. As these programs a…
  • $2.3 billion investment that will create nearly 500 skilled jobs. This facility
  • will
  • give us manufacturing flexibility across small molecules, biologics, and antibody drug con…
  • come.
  • In Indiana, RAISE Bio is investing more than $170 million to establish a new radio pharmac…
  • pipeline and advance our U.S. manufacturing commitments. Turning to slide five, as we look…
  • With
  • COBINFI, we will share open label Alzheimer's disease psychosis data from the ADEP 1 and f…
  • program, bipolar one data from the COBINFI balsam studies, and the first registrational re…
  • So
  • while we have made good progress in our pipeline, there's more to
  • come. As
  • we close out the year and move into 2027, we are focused on a few key priorities as noted …
  • Second, translating pipeline progress into filings, approvals, and successful launches. Zi…
  • focused on becoming faster and more efficient in RD, and over the past year, we have made …
  • technology. That discipline gives us flexibility to invest behind the growth portfolio and…
  • meaningful wins,
  • and
  • remain highly disciplined in ensuring our cost structure is aligned with our revenue base.…

Speaker 3

Unverified voice label

Thank you, Chris, and good morning, everyone. Our third quarter results reflect continued strong execution across our growth portfolio and continued strength from Eliquist. We remain focused on financial discipline, balancing investments and our growth drivers with continued productivity improvements. Based on our performance year-to-date and our outlook for the remainder of the year, we are further raising our full year guidance. Let me begin with a review of our third quarter results.

Starting with slide eight, total revenue in the third quarter increased 7% year over year to approximately $13.1 billion. Growth portfolio revenue rose 12% to $7.7 billion, driven by double-digit growth across several
products. Our legacy portfolio revenue increased 1%, with growth in Eloquist more than offsetting the declines from generic entry across the remainder of the legacy portfolio. Turning to product performance on slide nine, starting with oncology, for Opdevo, revenue decreased 6% year over year to approximately $2.4 billion, primarily reflecting continued conversion to Guvantic in the US and in Europe.

Juvantic continued its strong launch trajectory with revenue of $334 million, representing sequential growth of 28%, and is now annualizing at over $1.3 billion. Optolag delivered another quarter of strong double-digit growth driven by
continued global demand in its leading position as a standard of care and first-line melanoma in the U.S. Turning to slide 10, RebLazel grew 22% to $750 million, reflecting continued uptake in first-line MDS associated anemia.

Ryanzi posted 48% growth, resulting in revenue of $526
million, driven by its best-in-class profile and strong demand in both the US and in international markets. Moving to cardiovascular and immunology on slide 11, Eloquist revenue was approximately $4.7 billion, up 26% driven by net price, along with strong demand and continued market share gains. Eloquist sales in Q4 will be impacted by the upcoming LOE in Europe, which will be partially offset by the continued growth in the U.S.

Chemzios revenue increased 42% to $420 million, reflecting continued strong demand growth, including new patient starts and deeper penetration into the community setting. On a sequential basis, revenue was
impacted by the typical inventory drawdown during the third quarter, which we expect will normalize in the fourth quarter. ?Now moving to immunology. Global revenue for CETIC2 grew 25%. We are supporting the recent indication for psoriatic arthritis in adults and look forward to the upcoming phase three readouts in lupus expected by year end. ?

I
will wrap up our product performance review on slide 12 with neuroscience. ?The Bemfi revenue grew 33% to $57 million in the quarter. On a sequential basis, inventory destocking offset increased demand. We anticipate that revenue will more closely track prescription volume going forward. Let's now move to the PL on slide 13. Gross margin in the third quarter was 68.4%, reflecting product mix and to a lesser extent a one-time expense for a contract termination.

Operating expenses for the third quarter were $4.1 billion. We continue to benefit from a strategic productivity initiative, which is enabling us to reduce expenses in identified areas while maintaining flexibility to invest in multiple growth-oriented opportunities. Our effective tax rate in a
quarter was 14.1%, reflecting jurisdictional earnings mix and the impact of acquired in process RD charge. And we had a 58 cent per share impact from acquired in process RD and licensing income in the quarter.

Considering all these factors, diluted earnings per share was $1.35 for the quarter. Turning to the balance
sheet and capital allocation highlights on slide 14, we remain in a solid financial position with approximately $13 billion in cash equivalents and marketable securities as of September 30th, and we generated approximately $4.2 billion in operating cash flow during the quarter. ?In terms of capital allocation, we maintain a strategic and balanced approach to deploying our strong cash flows.

Business development remains a priority,
?and we are regularly evaluating opportunities in the therapeutic areas we know best while continuing to return cash to our shareholders through our commitment to the dividend. ?Now moving to guidance on slide 15, We are increasing our full year revenue guidance based upon our year-to-date results and our current projections for the balance of the year. When excluding the third quarter acquired in process RD charges and licensing income of $0.58 per share, the midpoint of our 2026 non-GAP EPS guidance would have increased by approximately 15 cents per share.

After including the 58 cents per share previously referenced, our expected non-GAP EPS guidance range for 2026 is now $6.35 to $6.55.

Passages & reports (24)
  • Thank you, Chris, and good morning, everyone. Our third quarter results reflect continued …
  • are further raising our full year guidance. Let me begin with a review of our third quarte…
  • products. Our legacy portfolio revenue increased 1%, with growth in Eloquist more than off…
  • reflecting continued conversion to Guvantic in the US and in Europe. Juvantic continued it…
  • continued global demand in its leading position as a standard of care and first-line melan…
  • million, driven by its best-in-class profile and strong demand in both the US and in inter…
  • will be impacted by the upcoming LOE in Europe, which will be partially offset by the cont…
  • impacted by the typical inventory drawdown during the third quarter, which we expect will …
  • Now
  • moving to immunology. Global revenue for CETIC2 grew 25%. We are supporting the recent ind…
  • I
  • will wrap up our product performance review on slide 12 with neuroscience.
  • The
  • Bemfi revenue grew 33% to $57 million in the quarter. On a sequential basis, inventory des…
  • and to a lesser extent a one-time expense for a contract termination. Operating expenses f…
  • quarter was 14.1%, reflecting jurisdictional earnings mix and the impact of acquired in pr…
  • sheet and capital allocation highlights on slide 14, we remain in a solid financial positi…
  • In
  • terms of capital allocation, we maintain a strategic and balanced approach to deploying ou…
  • and
  • we are regularly evaluating opportunities in the therapeutic areas we know best while cont…
  • Now
  • moving to guidance on slide 15, We are increasing our full year revenue guidance based upo…
  • have increased by approximately 15 cents per share. After including the 58 cents per share…

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 3

are maintaining our projections for gross margin, operating expenses, and tax rate while slightly lowering the expense level on our other income and expense ?line. Incorporated into these revisions is a total legacy portfolio revenue decrease, now expected to be between 3% and 5%, while we continue to expect Eloquis full year revenue growth of 20 to 25%.

Passages & reports (3)
  • are maintaining our projections for gross margin, operating expenses, and tax rate while s…
  • line.
  • Incorporated into these revisions is a total legacy portfolio revenue decrease, now expect…

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 3

closing, our strong performance year to date reinforces our confidence in the business. Remain focused on

Passages & reports (1)
  • closing, our strong performance year to date reinforces our confidence in the business. Re…

Speaker 3

And with that, I will now turn the call back over to Chuck for QA. Bethany, do we please poll

Passages & reports (1)
  • And with that, I will now turn the call back over to Chuck for QA. Bethany, do we please p…

Speaker 1

for questions?

Passages & reports (1)
  • for questions?

Speaker 0

We will now begin the question and answer session. To ask a question, you may press star, then one on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. We ask that you please limit yourself to one question. ?To withdraw your question, please press star, then two. At this time, we will pause momentarily to assemble our roster.

Passages & reports (3)
  • We will now begin the question and answer session. To ask a question, you may press star, …
  • To
  • withdraw your question, please press star, then two. At this time, we will pause momentari…

Questions & answers

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

first question today comes from Michael Yi with UBS. Please go ahead.

Passages & reports (1)
  • first question today comes from Michael Yi with UBS. Please go ahead.

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 4

Unverified voice label

guys, thanks for the question. Congrats on the good quarter. Recently you had results for the Admiral Parent uh drug, as you just mentioned, and there were some mixed results in the IPF study. Could you just comment a little bit about your confidence uh at the 120 MIG high dose, ?uh, which had some more mixed results, and whether you still expect that dose to be working and that you still have high confidence in 60 and 120 in the PPF study to complete the package?

Thank

Passages & reports (3)
  • guys, thanks for the question. Congrats on the good quarter. Recently you had results for …
  • uh,
  • which had some more mixed results, and whether you still expect that dose to be working an…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Thanks for the question, Mike. Uh Christian.

Passages & reports (1)
  • Thanks for the question, Mike. Uh Christian.

Speaker unclear

?Good morning, Mike.

Passages & reports (1)
  • Good morning, Mike.

Speaker 5

Unverified voice label

Thank you for the questions. First of all, let me tell you, I'm pleased with the positive top-line results for the phase three ALOFTA APF study. We believe, I believe, that this drug has the potential to be the first-in-class LPA1 antagonist. You know, in a setting like pulmonary fibrosis, that's very difficult to treat, and honestly, a very challenging drug development area. As we announced, the trial met the primary point at 60 milligram with statistically significant improvement in FEC.

And in
addition, we have seen an excellent safety and tolerability profile. This is both with 60 milligram BAD and 100 milligram uh BAD. For instance, the number of discontinuation for adverse events were lower or the same level of placebo. 120, going to your question, we have seen an improvement, a decline FEC, but not statistically significant. Our preclinical work demonstrated an adequate target coverage with both doses, 60 and 120.

But you may recall that we did not formally test 120 milligram in phase two setting
clinically, was a modeling. And we had a runin in the phase in the phase three study. So we continue to analyze the data, We continue to dig into the data. We will present the data in a medical medical meeting next year. Anyway, we are pleased with this outcome.

We will discuss these results
with health authorities, and we are looking forward to the outcome of PPF study happening next year. You know, we cannot predict what will be the outcome according to the doses, but we are testing both of them and we will see the outcome.

Passages & reports (6)
  • Thank you for the questions. First of all, let me tell you, I'm pleased with the positive …
  • antagonist. You know, in a setting like pulmonary fibrosis, that's very difficult to treat…
  • addition, we have seen an excellent safety and tolerability profile. This is both with 60 …
  • we have seen an improvement, a decline FEC, but not statistically significant. Our preclin…
  • clinically, was a modeling. And we had a runin in the phase in the phase three study. So w…
  • with health authorities, and we are looking forward to the outcome of PPF study happening …

Speaker 1

Thanks, Christian.

Passages & reports (1)
  • Thanks, Christian.

Speaker 0

The next question comes from Alex Hammond with Wolf Research. Please go ahead.

Passages & reports (1)
  • The next question comes from Alex Hammond with Wolf Research. Please go ahead.

Speaker unclear

?Thanks for

Passages & reports (1)
  • Thanks for

Speaker 6

Unverified voice label

taking the question. Since that burnamide was approved in August and Messi's approval is expected kind of mid-year next year. Because what are you seeing on the ground in the early weeks of launch? And what feedback are you hearing from the community and academic Myloma positions on uptake, tolerability, and where they're using it? Thank you.

Passages & reports (2)
  • taking the question. Since that burnamide was approved in August and Messi's approval is e…
  • Thank you.

Speaker 2

Thanks for the question, Alex. Adam.

Passages & reports (1)
  • Thanks for the question, Alex. Adam.

Speaker unclear

?So,

Passages & reports (1)
  • So,

Speaker 7

Unverified voice label

Alex, we are excited

Passages & reports (1)
  • Alex, we are excited

Speaker unclear

?to have launched Symbexis. It's the first

Passages & reports (1)
  • to have launched Symbexis. It's the first

Speaker 7

approved cell mod in the market. Now it's still early in the launch, but our teams are executing well. We're pleased with the adoption that we're seeing over the first few weeks on the market. And physician feedback has been positive, largely based on the strength of the MRD results as well as the simplicity of use. We're seeing use come from both the community and the hospital setting.

We do expect the majority of use to come from the community where 70 to 80% of patients are treated. So we'll see that longer term. You know, our teams are focused on establishing a broad base of prescribers and reinforcing
the efficacy, the safety, and quite frankly, the simplicity of using Zymbexis ?to replace revelimed and pomelus-based regimens. We also are excited about the PFS data, which will further augment the efficacy profile.

And we look forward to presenting these data at Ash. So, you
?know, we're seeing good commercial potential for Zymbexis and for Mazigdomide, we're excited to launch it as well and aim for both products to be foundational therapies in the community by replacing image over time.

Passages & reports (7)
  • approved cell mod in the market. Now it's still early in the launch, but our teams are exe…
  • of use. We're seeing use come from both the community and the hospital setting. We do expe…
  • the efficacy, the safety, and quite frankly, the simplicity of using Zymbexis
  • to
  • replace revelimed and pomelus-based regimens. We also are excited about the PFS data, whic…
  • know,
  • we're seeing good commercial potential for Zymbexis and for Mazigdomide, we're excited to …

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 1

Adam. Let's take our next question.

Passages & reports (1)
  • Adam. Let's take our next question.

Speaker 0

The next question comes from Seamus Fernandez with Guggenheim. Please go ahead.

Passages & reports (1)
  • The next question comes from Seamus Fernandez with Guggenheim. Please go ahead.

Speaker unclear

?Thank you

Passages & reports (1)
  • Thank you

Speaker 5

for the question. This

Passages & reports (1)
  • for the question. This

Speaker 4

is Zach Dunn

Passages & reports (1)
  • is Zach Dunn

Speaker unclear

?on for

Passages & reports (1)
  • on for

Speaker 5

Seamus Fernandez. Just to start, as you mentioned, there's been a series of positive phase three programs that have read out successfully and ?I'm not sure these are getting fully appreciated. So what do you think the market is missing from these readouts? And then focusing on the upcoming readout uh for milvexian in SSP.

Passages & reports (3)
  • Seamus Fernandez. Just to start, as you mentioned, there's been a series of positive phase…
  • I'm
  • not sure these are getting fully appreciated. So what do you think the market is missing f…

Speaker 4

Can based on the baseline characteristics and assuming the asyndesian time from index event data are reliable, how confident are you that SST can still be successful? I know we

Passages & reports (1)
  • Can based on the baseline characteristics and assuming the asyndesian time from index even…

Speaker 5

and ?a lot we have talked to have looked at those forest plots from Oceanic Stroke.

Passages & reports (3)
  • and
  • a
  • lot we have talked to have looked at those forest plots from Oceanic Stroke.

Speaker unclear

?So

Passages & reports (1)
  • So

Speaker 4

any uh color you can provide there would be helpful. Thank

Passages & reports (1)
  • any uh color you can provide there would be helpful. Thank

Speaker unclear

?you. Uh thanks for

Passages & reports (1)
  • you. Uh thanks for

Speaker 2

the question, Ben. Maybe um on the Milbexian question, Christian, you could start and then I'll uh close out with just uh your comments on the market.

Passages & reports (1)
  • the question, Ben. Maybe um on the Milbexian question, Christian, you could start and then…

Speaker 5

Um you you Shamos started with the the redoubts. Let me let me let me go there first. Uh uh we are pleased. Uh I'm pleased to see that this 2026 ?uh we are uh getting uh a very good uh uh pace, a very good flow. Last year, when we started and we discussed, we we explain how much scrutiny we we put in every single in every single trial to try to mitig mitigate risks that intrinsically every trial may have.

And I think this
is start to pay off. And what I'm pleased is that we have positive outcomes across therapeutic areas. In dermatology, in immunology, in uh we will have uh cell therapy. So this is uh this looks good. And if we close this year, because there are three remaining diseases, um SSP and uh the two SOTIC2 studies in lupus with positive outcome, I think we can we can we can be very pleased on the rate of success that we will uh score in 2026.

Your specific question SSP, I think uh uh I would put in the the big picture first. Uh this study was designed
based on a very solid phase two trial that we ran showing 30% risk reduction in strokes and uh with a very careful selection of the dose and the benefit risk profile efficacy safety. I imagine you refer to the randomization window that there are maybe different compare some competitive studies.

We based all the criteria when the patient randomized based on our own phase two and based on a prior phase three studies. And what I can tell you that the data are pointing that the randomization window that we selected
can provide uh could provide the best efficacy. So we're looking forward to see SSP uh data uh this year. And of course, we are also very eager to see the AFIB uh read out uh Q1 next year.

Passages & reports (8)
  • Um you you Shamos started with the the redoubts. Let me let me let me go there first. Uh u…
  • uh
  • we are uh getting uh a very good uh uh pace, a very good flow. Last year, when we started …
  • is start to pay off. And what I'm pleased is that we have positive outcomes across therape…
  • SOTIC2 studies in lupus with positive outcome, I think we can we can we can be very please…
  • based on a very solid phase two trial that we ran showing 30% risk reduction in strokes an…
  • window that there are maybe different compare some competitive studies. We based all the c…
  • can provide uh could provide the best efficacy. So we're looking forward to see SSP uh dat…

Speaker 7

Um Ben,

Passages & reports (1)
  • Um Ben,

Speaker unclear

?the only

Passages & reports (1)
  • the only

Speaker 2

thing I would just add on top of uh what Christian just said is in our discussions with investors, we have been very focused on emphasizing that the long term growth that we have, the long term focus that we have is building a strong company that can deliver sustained growth, particularly as we get into the next decade. To do that, we think we've got to continue to do, frankly, what we've demonstrated this year, which is drive the business that exists today.

You see that in our quarterly postings. Deliver on our late stage pipeline. Christian and team have done a really nice job of scrutinizing those studies.

Passages & reports (2)
  • thing I would just add on top of uh what Christian just said is in our discussions with in…
  • into the next decade. To do that, we think we've got to continue to do, frankly, what we'v…

Um, we're obviously happy with the results that we've seen with Arlosell's and Bexas at Milprund and RAISE 101. Um, we're looking forward to the additional readouts we have through the rest of this year and into next year. And as we discussed in our prepared remarks, being very disciplined in how we operate from a financial standpoint and executing consistently. We're obviously happy with the performance we've seen thus far, but ?the team is heads down in making sure we continue to deliver across each of those areas going forward.

Passages & reports (4)
  • Um, we're obviously happy with the results that we've seen with Arlosell's and Bexas at Mi…
  • a financial standpoint and executing consistently. We're obviously happy with the performa…
  • the
  • team is heads down in making sure we continue to deliver across each of those areas going …

Speaker 1

Thanks, Chris. Betsy, let's move to the next question, please.

Passages & reports (1)
  • Thanks, Chris. Betsy, let's move to the next question, please.

Speaker 0

The next question comes from Akash Tawari with Jeffries. Please go ahead.

Passages & reports (1)
  • The next question comes from Akash Tawari with Jeffries. Please go ahead.

Speaker 4

much. Um, can you frame the Admiliprint opportunity relative to some of the historical products in the space and also maybe investor expectations around Mulvaxine ?or Cubenfi? ?We're seeing Jackson have one of the best launches in IPF despite an a modest FEC, and PPF could be a bigger opportunity than IPF. So ?uh could this actually ?be one of your biggest products now that you have the I the IPF data?

And did Admiliprint

Passages & reports (9)
  • much. Um, can you frame the Admiliprint opportunity relative to some of the historical pro…
  • or
  • Cubenfi?
  • We're
  • seeing Jackson have one of the best launches in IPF despite an a modest FEC, and PPF could…
  • uh
  • could this actually
  • be one of
  • your biggest products now that you have the I the IPF data? And did Admiliprint

Speaker 7

show ?a benefit on time to

Passages & reports (3)
  • show
  • a
  • benefit on time to

Speaker unclear

?event

Passages & reports (1)
  • event

Speaker 4

or mortality in your IPF trial? Thank

Passages & reports (1)
  • or mortality in your IPF trial? Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 7

Adam,

Passages & reports (1)
  • Adam,

Speaker 2

do you want to take that and then Krishna you could chime in?

Passages & reports (1)
  • do you want to take that and then Krishna you could chime in?

Speaker 7

Yeah, gosh, thanks for the question. So, you know, we think there's a significant need that remains for new and improved disease modifying therapies in both IPF and PPF that are both effective and well tolerated. And that includes impacting how patients feel. It includes how patients function, and ultimately the impact on survival rates. As you know, is a dismal survival rates in both IPF and PPF. ?

You
know, we hear from KOLs that taking a holistic approach to the data is going to be important. And that includes, as you mentioned, looking at both the primary and the secondary endpoints of the study. We know that safety and tolerability will be a key area of differentiation for Admiralt. You know, even with the advent of newer therapies, GI tolerability and cough, they are challenging to manage, especially in an older comorbid patient population.

Passages & reports (5)
  • Yeah, gosh, thanks for the question. So, you know, we think there's a significant need tha…
  • rates. As you know, is a dismal survival rates in both IPF and PPF.
  • You
  • know, we hear from KOLs that taking a holistic approach to the data is going to be importa…
  • the advent of newer therapies, GI tolerability and cough, they are challenging to manage, …

Speaker 7

FPC, but also at Millperant demonstrated a well-tolerated safety profile where discontinuations due to adverse events were similar to placebo. So there's a real opportunity to gain share as effective ?and well-tolerated treatments like in Millperant come to market. We also expect the market to grow significantly. I've talked about this previously, where today it's a $4 billion market. We think this market could nearly double as we're going to start to see the creation of a large second-line line switch ?and our add-on market with newer treatments available.

We've got a number of pre launch activities underway with a focus on bringing in pulmonology expertise to the company, providing education to physicians on this new and promising mechanism. And we're also looking forward to the PPF readout early next year because that is the larger commercial
opportunity that can complement the IPF results.

Passages & reports (6)
  • FPC, but also at Millperant demonstrated a well-tolerated safety profile where discontinua…
  • and
  • well-tolerated treatments like in Millperant come to market. We also expect the market to …
  • and
  • our add-on market with newer treatments available. We've got a number of pre launch activi…
  • opportunity that can complement the IPF results.

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 2

Adam. Anything to add, Christian? Nakash,

Passages & reports (1)
  • Adam. Anything to add, Christian? Nakash,

Speaker 5

your question is more related to key secondary employing, some key the secondary employee outcomes. We didn't disclose this. Uh we we mentioned we took in the press release about the primary and some of the safety profile. I can tell you that uh we are pleased with the overall outcome of the trial, and we will present this data uh in a medical meeting next year.

Passages & reports (2)
  • your question is more related to key secondary employing, some key the secondary employee …
  • we will present this data uh in a medical meeting next year.

Speaker 1

Thanks, Christian. ?Uh let's move to our next question, please.

Passages & reports (3)
  • Thanks, Christian.
  • Uh
  • let's move to our next question, please.

Speaker 0

The next question comes from Matt Phipps with William Blair. Please go ahead.

Passages & reports (1)
  • The next question comes from Matt Phipps with William Blair. Please go ahead.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 1

this

Passages & reports (1)
  • this

Speaker unclear

?is Eric

Passages & reports (1)
  • is Eric

Speaker 3

Vaughn from MACFIPS. Just a question on the Adept trials. So with Adept timelines reiterated for 2027 again, ?I was wondering if you could give some specifics on current enrollment progress as well as site quality remediation, and if we should expect ?the Adept 1, 2, and 4 readouts to land together or be more staggered throughout the

Passages & reports (5)
  • Vaughn from MACFIPS. Just a question on the Adept trials. So with Adept timelines reiterat…
  • I was
  • wondering if you could give some specifics on current enrollment progress as well as site …
  • the
  • Adept 1, 2, and 4 readouts to land together or be more staggered throughout the

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 2

Thanks for the question. Christian, do you want to take that?

Passages & reports (1)
  • Thanks for the question. Christian, do you want to take that?

Speaker 5

Thank you, Matt, for the for the question. Let me start actually with the program status as you were asking for. Everything is tracking as we guided. We have a potential interim analysis for Adept One later this year, and we anticipate top line results, readouts for all the ADEPT program throughout 2027. Some readouts can coincide or can be more or less the same time or can be staggered.

there. You know, Adept One is event-driven, for instance. Uh, we I think Chris
mentioned uh in his opening remarks, we also expect on top of ADEP program the readouts of our bipolar one program in 2027. So very important here for COBENFI in terms of uh data flow. I want to point out one uh one aspect that is important uh uh to your attention.

In November, uh
we look forward to the CTAD presentation in Boston. There we will present two data sets. The first is the open label lead-in period from the ongoing ADEP 1 study. And the second data set is from the open label extension rollover study ADEP3. So both course, substantial number of patients, all patient treaty with COBENTI. This presentation will address some improvements in psychotic symptoms with CARXT.

And of course, we're waiting the randomized control studies to to to read out. But I think the CETA data are encouraging in our view and support, I believe
support ongoing development programs.

Passages & reports (6)
  • Thank you, Matt, for the for the question. Let me start actually with the program status a…
  • anticipate top line results, readouts for all the ADEPT program throughout 2027. Some read…
  • mentioned uh in his opening remarks, we also expect on top of ADEP program the readouts of…
  • we look forward to the CTAD presentation in Boston. There we will present two data sets. T…
  • course, substantial number of patients, all patient treaty with COBENTI. This presentation…
  • support ongoing development programs.

Speaker 2

Thanks, Richard.

Passages & reports (1)
  • Thanks, Richard.

Speaker 1

Great. Let's move to our next question, please.

Passages & reports (1)
  • Great. Let's move to our next question, please.

Speaker 0

The next question comes from Carter Gould with Cantor. Please go ahead.

Passages & reports (1)
  • The next question comes from Carter Gould with Cantor. Please go ahead.

Speaker 3

these studies in light of the Mdeltra frontline data and if that

Passages & reports (1)
  • these studies in light of the Mdeltra frontline data and if that

Speaker unclear

?uh augurs any sort of

Passages & reports (1)
  • uh augurs any sort of

Speaker 4

changes to your strategy. Thank you.

Passages & reports (1)
  • changes to your strategy. Thank you.

Speaker 2

Christian.

Passages & reports (1)
  • Christian.

Speaker 5

Thank you. Thank you for the good question. The data we have seen at ESMO are uh uh quite uh uh impressive and uh actually we welcome this data in a such a difficult disease uh uh like uh extended disease and small cellular cancer. Uh as you said, we have uh ongoing registrational studies with Atigo and combination of any volumum and standard chemotherapy.

The study is completed. We are just now looking at the redoubt. And we are running the combination with Pumetamic and standard chemotherapy. We don't know, of course,
the outcome of the study and how they can benchmark, but I think these are studies that allow us, first of all, to benchmark the activity of a novel mechanism of action like a TIGO in this space, but targeting an important antigen expressed in most of the patients with tumors with small cellular cancer tumors, but also for our PD1 BGF, this will give us a benchmark.

Because then we will prepare the next step. As you know, we started the combination with Pumitamig plus a DGL3 engager
?from Boringen England that we announced. So we are paving the road with an extra way because we believe our asset can play in this space, of course, through combinations with engagers.

Passages & reports (6)
  • Thank you. Thank you for the good question. The data we have seen at ESMO are uh uh quite …
  • you said, we have uh ongoing registrational studies with Atigo and combination of any volu…
  • the outcome of the study and how they can benchmark, but I think these are studies that al…
  • expressed in most of the patients with tumors with small cellular cancer tumors, but also …
  • from
  • Boringen England that we announced. So we are paving the road with an extra way because we…

Speaker 2

I think the only thing I would add is just that as you look at impressive data, and I would agree these are impressive data, over time in all of these hard-to-treat diseases, small cell being one of them, what's likely to occur is you're going to see patients continue to be subtyped and additional therapies be required to treat patients not only in initial lines of therapy but subsequent lines of therapy.

And I think at the end of the day, there's going to be room for multiple agents to be engaged to help treat these patients.

Passages & reports (2)
  • I think the only thing I would add is just that as you look at impressive data, and I woul…
  • therapies be required to treat patients not only in initial lines of therapy but subsequen…

Speaker 3

Thanks, Chris.

Passages & reports (1)
  • Thanks, Chris.

Speaker 1

Let's take our next question, please.

Passages & reports (1)
  • Let's take our next question, please.

Speaker 0

The next question comes from Courtney Breen with Bernstein. Please go ahead.

Passages & reports (1)
  • The next question comes from Courtney Breen with Bernstein. Please go ahead.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 6

Bristol team. Thank you so much for taking our question today. I just wanted to zoom into Melvixian and expectations in terms of the atrial fibrillation readout. Can you help us understand with regards to the Q1 release that we're expecting, are we likely to see the details, the numerical details in that press release, or are we just going to get a positive or uh or or not positive trial detailed there?

We're trying to figure out kind of how long do we need to wait throughout next year to actually get validation on the likely utilization of this product given that that non inferiority number
?on the primary endpoint is going to be so critical, and there's a wide range that can meet a successful trial. Thank you.

Passages & reports (4)
  • Bristol team. Thank you so much for taking our question today. I just wanted to zoom into …
  • press release, or are we just going to get a positive or uh or or not positive trial detai…
  • on
  • the primary endpoint is going to be so critical, and there's a wide range that can meet a …

Speaker 2

Thanks for the question, Courtney. Um, first of all, we understand that the AFIP study is an important opportunity. It's an important opportunity for us. There's obviously a lot of focus. Um, of course, I would I I'd be remiss not to remind everyone that we need to ?put this study in the context of a much broader and very rich pipeline that we've got.

Having said that, we get how important uh this readout is. In terms of how we're gonna communicate in our initial press release, look, we're going to work to give an accurate view of the outcome of the study
and a view that allows you to get a sense of the opportunity that we have with AFib. We understand that in that context, providing more specifics in the press release will likely be important.

But we're going to need to balance this, of course, with ensuring that we can communicate the data in a
more fulsome way at a future medical conference. So, what I can tell you is that we're going to be working with our partner on this program to strike that balance.

Passages & reports (5)
  • Thanks for the question, Courtney. Um, first of all, we understand that the AFIP study is …
  • put
  • this study in the context of a much broader and very rich pipeline that we've got. Having …
  • and a view that allows you to get a sense of the opportunity that we have with AFib. We un…
  • more fulsome way at a future medical conference. So, what I can tell you is that we're goi…

Speaker 3

Thanks, Chris.

Passages & reports (1)
  • Thanks, Chris.

Speaker 1

Uh let's take our next question, please.

Passages & reports (1)
  • Uh let's take our next question, please.

Speaker 0

The next question comes from Chris Schott with JP Morgan. Please go ahead.

Passages & reports (1)
  • The next question comes from Chris Schott with JP Morgan. Please go ahead.

Speaker 4

Uh great. Thanks so much. Uh just one follow up from an earlier question and

Passages & reports (1)
  • Uh great. Thanks so much. Uh just one follow up from an earlier question and

Speaker unclear

?then a

Passages & reports (1)
  • then a

Speaker 7

second

Passages & reports (1)
  • second

Speaker unclear

?one.

Passages & reports (1)
  • one.

Speaker 4

On on

Passages & reports (1)
  • On on

Speaker 7

IPF, I think you mentioned potential

Passages & reports (1)
  • IPF, I think you mentioned potential

Speaker 4

for add-on usage for the drug. I guess specifically there, do you think additional studies would be needed to maximize commercial value or would your existing data set here be be enough? And then just kind of the core question I had was just as we think about twenty twenty-seven, just any initial pushes and polls we need to think about in the business ?and maybe just extending that a little bit longer term.

Do you think there's anything the streets you know kind of getting wrong in terms of whether it's twenty seven, twenty eight, twenty nine kind of manage how the company's gonna manage through this this upcoming LOE cycle as you just think about kind of again
where consensus is currently? Thanks so

Passages & reports (5)
  • for add-on usage for the drug. I guess specifically there, do you think additional studies…
  • polls we need to think about in the business
  • and
  • maybe just extending that a little bit longer term. Do you think there's anything the stre…
  • where consensus is currently? Thanks so

Speaker unclear

?much. Hey,

Passages & reports (1)
  • much. Hey,

Speaker 2

Chris, do you uh Chris, thanks for the question, Chris. Uh Christian, do you want to start?

Passages & reports (1)
  • Chris, do you uh Chris, thanks for the question, Chris. Uh Christian, do you want to start…

Speaker 5

Let me let me start uh first of all, uh um the the study that we run uh, as you know, has an equal distribution uh of uh monotherapy and add-on uh uh treatments. And uh we don't comment on the outcome on subgroups uh you will see when we will present the data. Adam, do you want to add anything on the market needs?

Passages & reports (2)
  • Let me let me start uh first of all, uh um the the study that we run uh, as you know, has …
  • do you want to add anything on the market needs?

Speaker 7

I agree, Christian. That's why I talked Chris about the increasing ?and expanding size of the market because you ?know prior to the launch of this next wave of innovation in both IPF and PPF, you know, there was very little add-on and switch use because of the high rates of mortality. In fact, you know, 50% of patients in this disease, they do not survive five years.

And also, there's a very high level
of discontinuation. Half the patients discontinue treatment within 12 months. And so the creation of a very large second line switch andor add-on market after the use of generic OFEV and Espriate will become much more significant opportunity for these newer treatment options. So ?I said we look forward to the PPF readout. It's a larger commercial opportunity and ultimately will complement the positive IPF results.

Passages & reports (9)
  • I agree, Christian. That's why I talked Chris about the increasing
  • and
  • expanding size of the market because you
  • know
  • prior to the launch of this next wave of innovation in both IPF and PPF, you know, there w…
  • of discontinuation. Half the patients discontinue treatment within 12 months. And so the c…
  • significant opportunity for these newer treatment options. So
  • I
  • said we look forward to the PPF readout. It's a larger commercial opportunity and ultimate…

Speaker 2

David, do you want to comment on the 27 question?

Passages & reports (1)
  • David, do you want to comment on the 27 question?

Speaker 3

Yeah, thanks. And Chris, thanks for the question. Look, we feel really good about how the business is performing this year. And I think the three-quarters of beat and the momentum that we have as we exit 26 going into 27, that growth portfolio is um really performing well. And as uh we talked about earlier, ?you know, having eight products that are now annualizing over a billion dollars in that growth portfolio really shows the diversity of ?that.

Um,
not to mention, you know, the phase three trials that we've been talking about today coming out. We're looking forward to adding those to the portfolio uh as we head into next year. And then um, you know, I would say as on the other side, uh, as we already talked about with Eliquist, we anticipate that one and a half to two billion dollar step down in 27.

And lastly, our strategic productivity initiative, that $2 billion worth of efficiencies, that we um we're well on track to achieve that by the end
?of 27. So and then as we look at, you know, from a cash flow perspective, ?um, continue to have strong cash flow generation, you know, we ended with $13 billion of cash on hand, which gives us further

Passages & reports (11)
  • Yeah, thanks. And Chris, thanks for the question. Look, we feel really good about how the …
  • earlier,
  • you
  • know, having eight products that are now annualizing over a billion dollars in that growth…
  • that. Um,
  • not to mention, you know, the phase three trials that we've been talking about today comin…
  • anticipate that one and a half to two billion dollar step down in 27. And lastly, our stra…
  • of
  • 27. So and then as we look at, you know, from a cash flow perspective,
  • um,
  • continue to have strong cash flow generation, you know, we ended with $13 billion of cash …

Speaker 7

strategic flexibility as we think about the portfolio.

Passages & reports (1)
  • strategic flexibility as we think about the portfolio.

Speaker 3

So feeling really good about the execution this year and that continuing as we go into 27.

Passages & reports (1)
  • So feeling really good about the execution this year and that continuing as we go into 27.

Speaker 2

Chris, the only thing I would add is just that you know we've been consistent in saying what we're focused on and executing against that. Um, as we think about the business today, we feel good about the momentum we have going into Q4. We hope that and anticipate that will continue into 2027. ?Uh, we've got some wind at our back with respect to late stage development, but clearly there's a lot of focus we have as a company on strengthening RD and continuing to deliver not just on that late stage pipeline, but also progress the earlier pipeline uh so that we drive sustained growth over time. ?

And
then, of course, we're gonna be aligning our OpEx space as David just alluded to to the opportunity that sets in front of us while also investing in growth opportunities. We've been really disciplined about doing those things ?uh throughout the course of this year, and that's what we're gonna stay focused on.

Passages & reports (7)
  • Chris, the only thing I would add is just that you know we've been consistent in saying wh…
  • Uh,
  • we've got some wind at our back with respect to late stage development, but clearly there'…
  • And
  • then, of course, we're gonna be aligning our OpEx space as David just alluded to to the op…
  • uh
  • throughout the course of this year, and that's what we're gonna stay focused on.

Speaker unclear

?Thanks, Chris. Uh

Passages & reports (1)
  • Thanks, Chris. Uh

Speaker 1

Betsy, let's move to the next question, please.

Passages & reports (1)
  • Betsy, let's move to the next question, please.

Speaker 0

The next question comes from Asad Haider with Goldman Sachs. Please go ahead.

Passages & reports (1)
  • The next question comes from Asad Haider with Goldman Sachs. Please go ahead.

Speaker unclear

?Great. Uh

Passages & reports (1)
  • Great. Uh

Speaker 3

thanks for taking the questions and congrats

Passages & reports (1)
  • thanks for taking the questions and congrats

Speaker 7

on all the progress. Um, a couple of uh big picture questions for Chris. Uh first, just on DD, ?uh, given this remains a top capital allocation priority, would be curious to hear any updated thoughts on how you're thinking about ideal ideal ste stage of development, therapeutic area, deal structures, and even transformative deals. Um and then uh second, just would also be interested in hearing any updated framing on your efforts to embed AI across the research organization.

Uh know that you have partnerships with both Anthropic and NVIDIA. Uh on the Anthropic announcement earlier this week, they said that they are looking to accelerate drug development with Claude. Bristol was named as one of the six partners in that effort. So, what can you tell us about
the progress you're seeing across the organization with these partnerships, uh, particularly as it relates to any quantifiable metrics or KPIs that your teams are reporting back to you?

Thank you.

Passages & reports (5)
  • on all the progress. Um, a couple of uh big picture questions for Chris. Uh first, just on…
  • uh,
  • given this remains a top capital allocation priority, would be curious to hear any updated…
  • AI across the research organization. Uh know that you have partnerships with both Anthropi…
  • the progress you're seeing across the organization with these partnerships, uh, particular…

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 2

Asad. Maybe I'll start and then um Christian can chime in uh with the AI uh question specific to RD anyway. Let me start on the BD question. BD continues, as we said, consistently to be a top allocation priority. Uh we've got a very strong late stage pipeline, but we're always going to be looking for opportunities to source innovation externally if it makes sense for us to do so.

And the criteria that we're going to continue to use as to how we do that is we're going to be looking for things that opportunities that make sense for us from a scientific standpoint. They've got to fit
and align with us strategically. Clearly, if there are opportunities for us to strengthen the nearer-term growth portfolio, we're going to be keenly interested in looking at those.

And ultimately, across all of these deals, they have to
?make financial sense. In terms of size, we continue to be agnostic on the size of the deal. Far more critical to us is does it make sense for us to be the rightful owner of the opportunity? Does it make strategic sense and can we show value to our shareholders? And then in respect to uh therapeutic areas, ?uh, again, these are going to be we're going to focus mainly on those areas where we know well in therapeutic areas uh that makes sense for ?us.

Just uh maybe before I turn it over to Christian, let me comment briefly on uh AI investments. Look, AI, as we've said on previous calls, is an important area and investment for us. Uh we are focused really on thinking about how we can embed AI where it makes sense across the entire value
chain of the company, everything from early stage discovery through commercialization, manufacturing, and virtually all of our enabling functions.

Um and the way we think about that is setting very specific targets that ultimately can be incorporated into operational plans. We talked previously about the fact that you know we've put
forward a 20 to 30 percent reduction in drug testing timelines, cutting in half the time from drug target selection to lead molecule identification. Those are just two examples. ?Um while we're making AI tools broadly available at the enterprise level, we're also working towards targeted investments where we can articulate an ROI.

And as it relates to anthropic uh specifically, I think that agreement fits broadly into that strategy. But Christian, do you want to comment specifically on RD?

Passages & reports (14)
  • Asad. Maybe I'll start and then um Christian can chime in uh with the AI uh question speci…
  • looking for opportunities to source innovation externally if it makes sense for us to do s…
  • and align with us strategically. Clearly, if there are opportunities for us to strengthen …
  • make
  • financial sense. In terms of size, we continue to be agnostic on the size of the deal. Far…
  • uh therapeutic areas,
  • uh,
  • again, these are going to be we're going to focus mainly on those areas where we know well…
  • us.
  • Just uh maybe before I turn it over to Christian, let me comment briefly on uh AI investme…
  • chain of the company, everything from early stage discovery through commercialization, man…
  • forward a 20 to 30 percent reduction in drug testing timelines, cutting in half the time f…
  • Um
  • while we're making AI tools broadly available at the enterprise level, we're also working …

Speaker 5

Sure.

Passages & reports (1)
  • Sure.

Let me start telling that through AI, we are accelerating actually our research and development uh projects. This is uh now a concrete uh a concrete uh uh fact that we can start to measure. You need to break to break break down your research and development drug journey because doesn't exist one solution that can solve everything. So there are specific solutions that are more focusing on research, other from early development and then late development projects. ?

I
think in research and discovery, AI can impact the quality, but also the speed how you develop drug candidates and how you bring fundamentally new uh I and Ds to the organization. This is very tangible. We have a multiple example, happy to share offline, that we are now having place. In in development, AI can be helpful in increasing your efficiency in terms of optimizing cost, having a pace in the way you run your projects.

And then there is a second aspect that is increase your probability of technical
success. And this is something that we are integrating more and more in the way of working. Just the announcement of two days ago with Tempos Pathos is an example of it because we will put together data, large data set in neuroscience, and we will work to have models that can help us to predict outcome.

So it's a concrete uh thing that is happening and is helping in uh uh delivering our beautiful portfolio drugs that uh of course uh require pace.

Passages & reports (7)
  • Let me start telling that through AI, we are accelerating actually our research and develo…
  • development drug journey because doesn't exist one solution that can solve everything. So …
  • I
  • think in research and discovery, AI can impact the quality, but also the speed how you dev…
  • that we are now having place. In in development, AI can be helpful in increasing your effi…
  • success. And this is something that we are integrating more and more in the way of working…
  • predict outcome. So it's a concrete uh thing that is happening and is helping in uh uh del…

Speaker 2

David,

Passages & reports (1)
  • David,

Speaker unclear

?you want

Passages & reports (1)
  • you want

Speaker 7

to comment on the PD question?

Passages & reports (1)
  • to comment on the PD question?

Speaker 3

Yeah, so

Passages & reports (1)
  • Yeah, so

Speaker unclear

?thanks for the question on

Passages & reports (1)
  • thanks for the question on

Speaker 3

BD. Look, we're actively evaluating multiple opportunities across varying deal structures,

Passages & reports (1)
  • BD. Look, we're actively evaluating multiple opportunities across varying deal structures,

Speaker 7

partnerships,

Passages & reports (1)
  • partnerships,

Speaker 3

licensing, and

Passages & reports (1)
  • licensing, and

Speaker 7

where

Passages & reports (1)
  • where

Speaker 3

appropriate, acquisitions. So, ?you know, our North Star on this is about strong sustainable growth late into the decade. And that's what we remain focused on. We're going to ?be, you know, financially disciplined around this approach, but also strategic aligned. And as we've done in the past, it's going to be in the therapeutic areas that we have the scientific capabilities, but as well as the commercial

Passages & reports (5)
  • appropriate, acquisitions. So,
  • you
  • know, our North Star on this is about strong sustainable growth late into the decade. And …
  • be, you
  • know, financially disciplined around this approach, but also strategic aligned. And as we'…

Speaker 7

strength to maximize the value of that. So we're we remain very active and we're gonna stay focused and financially

Passages & reports (1)
  • strength to maximize the value of that. So we're we remain very active and we're gonna sta…

Speaker 3

disciplined.

Passages & reports (1)
  • disciplined.

Speaker 2

Thanks David.

Passages & reports (1)
  • Thanks David.

Speaker unclear

?Great.

Passages & reports (1)
  • Great.

Speaker 3

Uh ?let's move to

Passages & reports (3)
  • Uh
  • let's move
  • to

Speaker 1

the next question, please, Betsy.

Passages & reports (1)
  • the next question, please, Betsy.

Speaker 0

The next question comes from Mohit Pansal with Wells Fargo. Please go ahead.

Passages & reports (1)
  • The next question comes from Mohit Pansal with Wells Fargo. Please go ahead.

Speaker unclear

?Great. Thank you very much for taking my

Passages & reports (1)
  • Great. Thank you very much for taking my

Speaker 3

question.

Passages & reports (1)
  • question.

Speaker unclear

?And I want

Passages & reports (1)
  • And I want

Speaker 4

to turn attention to Coben Pi, if I may. So it does look like this quarter you saw 30% year ?over year growth, but the numbers ?still appear modest relative to

Passages & reports (5)
  • to turn attention to Coben Pi, if I may. So it does look like this quarter you saw 30% yea…
  • over
  • year growth, but the numbers
  • still appear modest relative
  • to

Speaker unclear

?what we were all thinking about, how big this asset could be. So

Passages & reports (1)
  • what we were all thinking about, how big this asset could be. So

Speaker 7

maybe this is a question for Adam. Like,

Passages & reports (1)
  • maybe this is a question for Adam. Like,

Speaker unclear

?how what are you seeing the large as the largest constraint here? Is it the identification of patients or

Passages & reports (1)
  • how what are you seeing the large as the largest constraint here? Is it the identification…

Speaker 7

physician willingness to prescribe, tolerability? What exactly is going ?on? And how do you think examers may be different than what you're seeing in schizophrenia? Thank

Passages & reports (3)
  • physician willingness to prescribe, tolerability? What exactly is going
  • on?
  • And how do you think examers may be different than what you're seeing in schizophrenia? Th…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Thanks for the question, Adam. Yeah,

Passages & reports (1)
  • Thanks for the question, Adam. Yeah,

Speaker 7

Maui, thanks for the question. So we expect Cobanfi to deliver continued growth on schizophrenia with significant upside potential from future label expansions. In the quarter, you're right, we saw you know 30% growth year over year, but but we also saw quarter on quarter, a roughly three to four percent growth in total prescription volume, but net sales were impacted by an inventory decrease, which followed an inventory build in Q2, like we see with you know many products in our portfolio.

We expect that this will normalize in Q3 Q4, and as such, the um the growth will continue to track along with
the TRX ?uh increase that we expect to see. Now we're seeing several positive leading indicators to the brand. We're we're driving consistent increases in new prescribers with the number of prescribers doubling from last year. We've established differentiation across negative and cognitive symptoms of schizophrenia.

However, you know, we have clear areas where we need to make
further progress. We need to accelerate new patient starts, we need to improve repeat prescribing. ?I think one of the bigger challenges that we've seen is we we've been educating physicians on the importance of rapidly titrating Cobenphy to the effective dose of 125 milligrams. To do that, you know, in order to do that, that's the way physicians will maximize efficacy.

They can use antiemetics when needed to help minimize
nausea and vomiting, which occurs within the first few weeks of initiation. And there's still far too many patients that we see remaining on the 50 or 100 milligram dose. ?So when patients are on an effective dose and the GI toxicity is managed appropriately, we have truly seen remarkable results for this product. Now, as a result, as it uh pertains to Alzheimer's disease, you know, as you know, this is a much larger market.

Roughly 7 million people diagnosed with Alzheimer's disease in the
US, and 30 to 50 percent of patients have psychosis, whether that's hallucinations and or delusions or agitation. They also have um virtually all patients have cognitive uh impairment. And so this is a fundamentally different market than schizophrenia. There are no approved treatments today in ADP. Alzheimer's patients with psychosis have been treated off label for many years with D2s.

And unlike schizophrenia, what you see is PCPs and nurse practitioners and PAs are responsible for treating the majority of patients with 50% of patients treated in a long-term care facility. And why is that important? Well, in addition,
antipsychotics have significant safety limitations. They carry box warnings that are specific to elderly patients with dementia. And we know that D2s are associated with long-term side effects like sedation, cognitive impairment, and movement disorders that are significant issues for long-term care facilities where they need to carefully monitor off-label utilization of antipsychotics. ?

So
safety becomes increasingly important in an elderly patient population. And we know Cobenpi is not associated with those adverse events, doesn't carry a box warning. But that said, we will take the learnings from schizophrenia, and we're going to need to set appropriate expectations with patients and physicians, build confidence around managing the nausea and vomiting with Cobenfi. ?But Cobenfi would be the first product approved for ADP, and we believe has the potential to play a really important role in treating these patients over

Passages & reports (20)
  • Maui, thanks for the question. So we expect Cobanfi to deliver continued growth on schizop…
  • percent growth in total prescription volume, but net sales were impacted by an inventory d…
  • the TRX
  • uh
  • increase that we expect to see. Now we're seeing several positive leading indicators to th…
  • further progress. We need to accelerate new patient starts, we need to improve repeat pres…
  • I
  • think one of the bigger challenges that we've seen is we we've been educating physicians o…
  • nausea and vomiting, which occurs within the first few weeks of initiation. And there's st…
  • So
  • when patients are on an effective dose and the GI toxicity is managed appropriately, we ha…
  • US, and 30 to 50 percent of patients have psychosis, whether that's hallucinations and or …
  • with psychosis have been treated off label for many years with D2s. And unlike schizophren…
  • antipsychotics have significant safety limitations. They carry box warnings that are speci…
  • long-term care facilities where they need to carefully monitor off-label utilization of an…
  • So
  • safety becomes increasingly important in an elderly patient population. And we know Cobenp…
  • vomiting with Cobenfi.
  • But
  • Cobenfi would be the first product approved for ADP, and we believe has the potential to p…

Speaker unclear

?time.

Passages & reports (1)
  • time.

Speaker 1

Right. ?Thanks, Adam. ?Let's go to our next question, please.

Passages & reports (5)
  • Right.
  • Thanks,
  • Adam.
  • Let's go to our
  • next question, please.

Speaker 0

The next question comes from David M. Selom with Piper Sandler. Please go ahead.

Passages & reports (1)
  • The next question comes from David M. Selom with Piper Sandler. Please go ahead.

Speaker unclear

?hey, thanks.

Passages & reports (1)
  • hey, thanks.

Speaker 3

So another phase three readout you had recently was raised one oh one, and with that in mind, ?I know it was only interim uh data, but maybe talk through uh just the path forward from a regulatory

Passages & reports (3)
  • So another phase three readout you had recently was raised one oh one, and with that in mi…
  • I
  • know it was only interim uh data, but maybe talk through uh just the path forward from a r…

Speaker unclear

?perspective and also contextualize

Passages & reports (1)
  • perspective and also contextualize

Speaker 3

uh the market opportunity here, the addressable patient population, both US and X US, and how you're thinking about peak sales potential. Thank you.

Passages & reports (1)
  • uh the market opportunity here, the addressable patient population, both US and X US, and …

Speaker 2

Thanks for the question. Um maybe start with Christian and then Adam.

Passages & reports (1)
  • Thanks for the question. Um maybe start with Christian and then Adam.

Speaker 5

Thank you, David, for the question. Uh we're truly excited about this readout because, as Chris was mentioning in his open remarks, is a first. There are three reasons. The first is alpha, uh, actinium-based uh radiolygans are working post-lutition and potentially can work uh instead of routition. This is the first uh the first take-home message for me. The second is BMS is the first with this novel modality, and the third is uh the confidence in the platform, because this readout uh in gap net very important, but uh as you know, RASE Bio is uh a very important uh I and D engine for uh uh our organization.

Uh we have uh programs uh in uh uh we have a backup molecule in this space, a better molecule, and we have uh programs uh in liver cancer, GPC3, and in
prostate cancer, SCP3, novel target, and there are a few others, of course, that are coming up. So this is an important outcome that we will be presented in terms of the phase three readout next year.

And of course, the team started interacting with our authorities. Adam?

Passages & reports (4)
  • Thank you, David, for the question. Uh we're truly excited about this readout because, as …
  • post-lutition and potentially can work uh instead of routition. This is the first uh the f…
  • know, RASE Bio is uh a very important uh I and D engine for uh uh our organization. Uh we …
  • prostate cancer, SCP3, novel target, and there are a few others, of course, that are comin…

Speaker 7

Yes, so just to add on to what Christian said, we're pleased with the positive data readout of RAIS 101. This will be the first product launched from our radio pharmaceutical platform. So positive PFS interim data in SSTR2, positive GEPNATs, it does validate our highly potent actinium based approach. Just remember, GEP NETs are rare tumors. We estimate the incidence of GEPNATs at approximately 18,000 patients diagnosed annually in the United States.

When you look at patients who are progressing from Lutothera, it's roughly 70% of patients will go on to need a subsequent
therapy. And so while there are no approved treatments today, our focus will be on establishing RAIDS 101 as the clear standard of care after Lutothera. Commercially, it's a relative modest opportunity. However, bigger picture, we see RAID Bio as a true IND engine with multiple INDs expected in the next five years to ultimately enhance our oncology portfolio with a unique platform and pipeline.

Passages & reports (4)
  • Yes, so just to add on to what Christian said, we're pleased with the positive data readou…
  • approach. Just remember, GEP NETs are rare tumors. We estimate the incidence of GEPNATs at…
  • therapy. And so while there are no approved treatments today, our focus will be on establi…
  • ultimately enhance our oncology portfolio with a unique platform and pipeline.

Speaker 1

Thanks, Adam

Passages & reports (1)
  • Thanks, Adam

Speaker unclear

?and Christian.

Passages & reports (1)
  • and Christian.

Speaker 7

Betsy, let's move

Passages & reports (1)
  • Betsy, let's move

Speaker unclear

?to the next question, please.

Passages & reports (1)
  • to the next question, please.

Speaker 0

The next question comes from Jeff Meachum with Citibank. Please go ahead.

Passages & reports (1)
  • The next question comes from Jeff Meachum with Citibank. Please go ahead.

Speaker unclear

?All right.

Passages & reports (1)
  • All right.

Speaker 7

Uh morning everyone. Thanks for the question. ?Um was curious

Passages & reports (3)
  • Uh morning everyone. Thanks for the question.
  • Um
  • was curious

Speaker unclear

?of the pace

Passages & reports (1)
  • of the pace

Speaker 3

of conversion to QBantic. Maybe just help us with how far along that transition is today. And then strategically, ?you know, how much of a priority is that relative to say Pomidamig or the RAISE Bio program? I'm just trying to think of like how you guys view the oncology franchise for you over the kind of longer term in the mix there. Thank you.

Passages & reports (3)
  • of conversion to QBantic. Maybe just help us with how far along that transition is today. …
  • you know,
  • how much of a priority is that relative to say Pomidamig or the RAISE Bio program? I'm jus…

Speaker 2

Thanks for the question, Jeff. Uh maybe Adam, you start with Cubantic, and then I can kind of chime in on the second part of that question.

Passages & reports (1)
  • Thanks for the question, Jeff. Uh maybe Adam, you start with Cubantic, and then I can kind…

Speaker 7

Sure. Thanks, Jeff. You know, we're pleased with Cubantic performance. The team continues to deliver strong commercial performance and execution. Jeff, we've now converted roughly 17% of IV to sub Q launched to date. We're seeing increasing use across multiple tumors with uptake in our monotherapy indications as well as in combination. And we routinely hear feedback from the community specifically that Qantic improves practice efficiency with a three minute in office subcutaneous injection.

And patients prefer Cubantic when offered the opportunity for this formulation and truly novel technology.

Passages & reports (2)
  • Sure. Thanks, Jeff. You know, we're pleased with Cubantic performance. The team continues …
  • combination. And we routinely hear feedback from the community specifically that Qantic im…

So we're tracking well against our expectation that physicians will convert at least 30 to 40 percent of our IV business to Qvantic. We're tracking towards the higher end of that range. And we're pleased with the Qantic performance and what this means for patients and physicians.

Passages & reports (1)
  • So we're tracking well against our expectation that physicians will convert at least 30 to…

Speaker 2

And look, the way we think about oncology treatments generally is that we're going to be looking for opportunities to first of all bring differentiated platforms and products to market to help patients across multiple tumors and different lines of therapy, as we talked about to the previous question on small cell. And what I'm excited about as to where the pipeline is going is what you see playing out is that we've got very exciting platforms that are beginning to produce meaningful medicines.

You see that in our CART program, which continues to perform very well. We're very
excited about subsequent opportunities that we have there with products like Arlocel. You see that in the Cellmod program with Isabrand and with Iber and Mezi. And of course, that is a platform that's going to continue to produce new INDs as well as new products. We referenced in the prepared remarks, cocotamide.

The RAISE 101, as you just heard, is the first of what we believe is going to be an important radio pharmaceutical platform. And then if you go beyond platforms and just look at potentially differentiated assets, you've got products like Pumi, which you reference. I would uh be remiss to
not mention Isabrand, which showed very good data at ESMO. Um so we have a number of products there, and we would put Quvantic into that context.

QVANT is an important new medicine for patients that improves upon the existing therapies that we have, notably Opdevo in immunooncology.

Passages & reports (5)
  • And look, the way we think about oncology treatments generally is that we're going to be l…
  • And what I'm excited about as to where the pipeline is going is what you see playing out i…
  • excited about subsequent opportunities that we have there with products like Arlocel. You …
  • the prepared remarks, cocotamide. The RAISE 101, as you just heard, is the first of what w…
  • not mention Isabrand, which showed very good data at ESMO. Um so we have a number of produ…

So we've got a nice uh uh pipeline of differentiated products and platforms, and we're excited to continue to bring those forward and help a lot of patients across tumors.

Passages & reports (1)
  • So we've got a nice uh uh pipeline of differentiated products and platforms, and we're exc…

Speaker 3

Nice, Chris.

Passages & reports (1)
  • Nice, Chris.

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 1

next question, please, operator.

Passages & reports (1)
  • next question, please, operator.

Speaker 0

The next question comes from Sheng Yan with RBC. Please go ahead.

Passages & reports (1)
  • The next question comes from Sheng Yan with RBC. Please go ahead.

Speaker unclear

?Hi guys, thanks for squeezing me in. Um so

Passages & reports (1)
  • Hi guys, thanks for squeezing me in. Um so

Speaker 4

you ?recently disclosed a patient in your phase one autoimmune CART trial uh died of sepsis pneumonia after zolar cell infusion. Um you said it's unrelated to the June pause, but the patient had a late onset of non-ICANNS motor symptoms. Can you perhaps walk us through your updated thoughts on the path forward for zolar cell in autoimmune and the risk reward uh for CART in autoimmune?

Thanks very much.

Passages & reports (4)
  • you
  • recently
  • disclosed a patient in your phase one autoimmune CART trial uh died of sepsis pneumonia af…
  • zolar cell in autoimmune and the risk reward uh for CART in autoimmune? Thanks very much.

Speaker 2

Thanks for the question. Christian, you want to start?

Passages & reports (1)
  • Thanks for the question. Christian, you want to start?

Speaker 5

Sure. Thanks, uh Shrank, for the for the question. Let me start telling you that we truly remain excited about Zola Cell program because when we look at the totality of our data, we had uh 190 patients treated in phase one. The overall safety and efficacy profile uh of this product is a truly compelling. Zola cell provided provided a meaningful uh benefit to patients that have a severe autoimmune disorder, some of them with organ damage already, and many of these patients remain off disease modifying therapies.

So the potential is all there. As
we said, we implemented a voluntary pause to review clinical data across the program. This is the reason why the program is posed currently. But after an extensive analysis of all our data, we identified that the root cause was a change that we made in the selection and activation of a reagent.

Passages & reports (3)
  • Sure. Thanks, uh Shrank, for the for the question. Let me start telling you that we truly …
  • uh of this product is a truly compelling. Zola cell provided provided a meaningful uh bene…
  • we said, we implemented a voluntary pause to review clinical data across the program. This…

We are now made the proper adjustment of it and we are working with authority to restart the clinical program as soon as possible. Going to your question on the grade five, that was one fat, unfortunately, one fatal case of second pneumonia. It's the only grade five event across all Zola cell program out of 190 patients. So we are fully committed with all our expertise in cell therapy uh to bring uh this product discartee in autoimmune diseases.

Passages & reports (2)
  • We are now made the proper adjustment of it and we are working with authority to restart t…
  • Zola cell program out of 190 patients. So we are fully committed with all our expertise in…

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 2

Chung, maybe let me make one additional comment on Zola cell. Look, I have the uh distinction of having been in cell therapy before we thought it would work in hematology, never mind autoimmune diseases like ?uh late line lupus or MS. And remember, ?uh the patients that we're enrolling in these studies are patients with very severe, debilitating, and in many cases life threatening disease.

And our goal here is to achieve immune reset and hopefully by doing so enable long-term durable remissions. When you're doing drug development, as Christian alluded to, in very difficult to treat settings with
a new modality like this, you're always going to be evaluating the benefit risk profile. But the way you do that is the way we've done it, which is to be very rigorous in setting up a strong DMC, working with the best investigators in the field, and engaging transparently with regulators.

And what I
will tell you with Zola cell specifically is we are seeing potentially transformational activity. We're excited to continue this program. So what we're going to do is continue to be rigorous in how we conduct the study, be transparent with the broader community. But I'll tell you our investigators and we are excited to see the potential of this product in this modality.

Passages & reports (8)
  • Chung, maybe let me make one additional comment on Zola cell. Look, I have the uh distinct…
  • uh
  • late line lupus or MS. And remember,
  • uh
  • the patients that we're enrolling in these studies are patients with very severe, debilita…
  • a new modality like this, you're always going to be evaluating the benefit risk profile. B…
  • will tell you with Zola cell specifically is we are seeing potentially transformational ac…
  • the potential of this product in this modality.

Speaker 1

Thanks, Chris. Albreto, let's take our last question and then Chris will give a quick wrap-up.

Passages & reports (1)
  • Thanks, Chris. Albreto, let's take our last question and then Chris will give a quick wrap…

Speaker 0

The last question today comes from Evan Siegerman with BMO Capital Markets. Please go ahead.

Passages & reports (1)
  • The last question today comes from Evan Siegerman with BMO Capital Markets. Please go ahea…

Speaker unclear

?Hi guys,

Passages & reports (1)
  • Hi guys,

Speaker 3

thank you so much for taking my question. I want to ask the BD one slightly differently. ?You know, there's been a bit of a disconnect in the amount

Passages & reports (3)
  • thank you so much for taking my question. I want to ask the BD one slightly differently.
  • You
  • know, there's been a bit of a disconnect in the amount

Speaker 2

that you've spent in BD over the past 12 months versus some of your peers. So does

Passages & reports (1)
  • that you've spent in BD over the past 12 months versus some of your peers. So does

Speaker 3

this rep

Passages & reports (1)
  • this rep

Speaker 2

does this difference primarily

Passages & reports (1)
  • does this difference primarily

Speaker 3

reflect valuation, discipline, confidence in your internal pipeline, or your

Passages & reports (1)
  • reflect valuation, discipline, confidence in your internal pipeline, or your

Speaker 2

ability to grow the growth portfolio to fill ?the LOE gap? Any color

Passages & reports (3)
  • ability to grow the growth portfolio to fill
  • the LOE gap?
  • Any color

Speaker 3

would be great. Thank you so much.

Passages & reports (1)
  • would be great. Thank you so much.

Speaker 2

Sure. Thanks for the question, Evan. Um well, first of all, let me reiterate what I said before, which is that BD continues to be a top allocation, uh capital allocation priority. I think David provided a nice view of how we think about uh the types of deals that we have and will continue to be looking at. Uh we're certainly not waiting for anything.

Um uh if there's an opportunity that makes sense financially for us, can improve our ability to s to deliver sustained growth, we have the capacity to be in the mix. And what I would say is we continue to be very active um
in the space. Um and if a deal we think makes sense for us, ?uh, we're going to be engaged. That's been what the approach we've taken over the last number of years, and that's going to be continue to be our focus going forward.

So with that, I want to just say a big thank you to everyone for joining the call today. I know today in particular is
a busy day. Let me just say in closing that we are delivering strong performance from an increasingly diversified growth portfolio. As you've seen over the last few months, our pipeline is coming into focus and beginning to translate into new launches.

And importantly, we continue to be operating with financial discipline. As we
continue to execute, we're well positioned to deliver long term durable growth into the next decade. But of course, none of this happens by accident. And so I want to give a very sincere thank you to my colleagues around the world for their continued focus and commitment on the mission that we have to serve the patients who need our medicines.

So thank you all for joining us today. And as always, the teams available for follow

Passages & reports (8)
  • Sure. Thanks for the question, Evan. Um well, first of all, let me reiterate what I said b…
  • to be looking at. Uh we're certainly not waiting for anything. Um uh if there's an opportu…
  • in the space. Um and if a deal we think makes sense for us,
  • uh,
  • we're going to be engaged. That's been what the approach we've taken over the last number …
  • a busy day. Let me just say in closing that we are delivering strong performance from an i…
  • continue to execute, we're well positioned to deliver long term durable growth into the ne…
  • serve the patients who need our medicines. So thank you all for joining us today. And as a…

Speaker 0

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Passages & reports (1)
  • The conference has now concluded. Thank you for attending today's presentation. You may no…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

2 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 2. Unassigned words: 236. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T22:33:50.244Z.
Transcript version v1-9f3f16f03a46858fdeaf · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.